Chanazone 1g Oral Powder for Horses

Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

Presentation

Each Chanazone sachet contains: 1g of Phenylbutazone. Off white to yellow powder

Uses

Chanazone powder is indicated for the treatment of musculoskeletal conditions in the horse where relief from pain and a reduction in the associated inflammation is required, e.g. in lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation, particularly where continued mobility is considered desirable. It is also of value in limiting post surgical inflammation, myositis and other soft tissue inflammation. Phenylbutazone powder can be used as an anti-pyretic where this is considered advisable e.g. in viral respiratory infections.

Dosage and administration

• For oral use.
• The recommended dose rate is 4.4 – 8.8 mg/kg per day.
• For each 450 kg bodyweight the following dosage guide should be used according to individual response:
• Day 1 – 4.4 mg phenylbutazone/kg of bodyweight twice daily, (equivalent to two sachets or 10 g of the product twice daily).
• Day 2 – 4 2.2 mg phenylbutazone /kg of bodyweight twice daily, (equivalent to one sachet or 5 g of the product twice daily) followed by 2.2 mg phenylbutazone /kg of bodyweight daily, (equivalent to one sachet or 5 g of the product daily) or on alternate days as required.
• If no response is evident after 4-5 days, discontinue treatment.
• Hay may delay the absorption of Chanazone and so the onset of a clinical effect. It is advisable not to administer hay immediately prior to, or during the administration of the product.
• For ease of administration the product may be mixed with a quantity of bran or oats before each treatment.
• The therapeutic index of phenylbutazone is low.
• Do not exceed the stated dose or duration of treatment.

Special precautions for use in animals:

• Do not exceed the stated dose of 8.8 mg/kg/day as the therapeutic index of phenylbutazone is low. Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require careful clinical management.

Use during pregnancy and lactation:

Care should be exercised if administered to pregnant mares. Although no adverse effects of phenylbutazone on the foetus or maintenance of pregnancy have been reported during field use, no definitive safety studies have been carried out in the mare. Foetotoxic effects of phenylbutazone have been recorded in experimental animal species at high dose levels. Use of Chanazone in pregnant and lactating mares only according to a benefit/risk assessment by the responsible veterinarian Avoid use around time of parturition.

SPC and data sheet